In terms of safety, Melan-A expression being restricted to the melanocytic lineage, the injection of T-cells specific reactive against this antigen may cause vitiligo by killing normal melanocytes which is an acceptable adverse effect considering the severity of metastatic melanoma [2]. Here, MLANA is linked to metastatic melanoma.